traM Antibody

What is TRAM/TICAM2 and what is its role in cellular signaling?

TRAM (TRIF-related adaptor molecule), also known as TICAM2 (TIR domain-containing adapter molecule 2), is a critical protein in the MyD88-independent signaling pathway of Toll-like receptor 4 (TLR4). TRAM contains a central TIR domain that is most similar to that of TRIF and plays an essential role in the innate immune response . The functional absence of TRAM in vascular endothelial cells restricts TLR4 signaling to the MyD88-dependent pathway, highlighting its importance as a pathway-specific adaptor protein . TRAM functions by binding members of the IRAK family, ultimately leading to the activation of NF-κB . Mouse TRAM is a 232 amino acid, 26 kDa protein that shares 75% and 77% identity with human and rat TRAM, respectively .

What types of TRAM antibodies are available for research applications?

Research-grade TRAM antibodies are available in several formats with distinct characteristics:

Each antibody has been validated for specific applications, with polyclonal antibodies generally offering broader epitope recognition while monoclonals provide higher specificity and consistency .

How can I determine which TRAM antibody is appropriate for my experimental system?

When selecting a TRAM antibody, consider these critical factors:

• Species compatibility: Verify the antibody recognizes TRAM in your experimental organism. While mouse TRAM shares 75% sequence identity with human TRAM, epitope-specific antibodies may have variable cross-reactivity .

• Application validation: Review the validation data for your specific application. For example, AF4348 has been validated for Western blot in human Burkitt's lymphoma (Raji), mouse myoblast (C2C12), and rat kidney (NRK) cell lines .

• Subcellular localization: TRAM typically shows cytoplasmic localization, as demonstrated across multiple cell types using immunofluorescence techniques .

• Molecular weight detection: Prepare to observe TRAM at approximately 31 kDa in mouse samples and 43 kDa in human samples , considering potential post-translational modifications.

• Reactivity with related proteins: Consider potential cross-reactivity with other TIR domain-containing proteins when interpreting results.

What are the optimal conditions for Western blot detection of TRAM?

For successful Western blot detection of TRAM/TICAM2, implement these methodological approaches:

• Sample preparation:

  • Use appropriate cell models: TRAM has been successfully detected in Raji human Burkitt's lymphoma, C2C12 mouse myoblast, NRK rat kidney, Jurkat, HeLa, and 293T cell lines .

  • For tissue samples, TRAM has been detected in rat brain, kidney, and mouse placenta tissue lysates .

• Electrophoresis and transfer conditions:

  • PVDF membrane is recommended for optimal protein transfer .

  • Use reducing conditions with appropriate buffer systems (Immunoblot Buffer Group 1 or 2 has been validated) .

• Antibody dilutions and detection:

  • For AF4348 (polyclonal): 1 μg/mL concentration has shown specific detection .

  • For MAB4348 (monoclonal): 2 μg/mL concentration is optimal .

  • For 12705-1-AP (polyclonal): 1:500-1:2000 dilution range is recommended .

  • Use compatible secondary antibodies (HRP-conjugated anti-goat or anti-rabbit, depending on primary) .

• Expected results:

  • A specific band at approximately 31 kDa for mouse TRAM and 43 kDa for human TRAM .

How should I optimize immunofluorescence protocols for TRAM detection?

For robust immunofluorescence detection of TRAM:

• Cell preparation and fixation:

  • Use immersion fixation with paraformaldehyde for adherent and suspension cells .

  • Permeabilize with saponin to access intracellular TRAM protein .

• Antibody incubation parameters:

  • For AF4348: 10 μg/mL for 3 hours at room temperature has been validated .

  • For MAB43481: 10 μg/mL for 3 hours at room temperature is recommended .

  • For 12705-1-AP: 1:10-1:100 dilution range is suggested .

• Detection systems:

  • NorthernLights™ 557-conjugated secondary antibodies have been validated for TRAM detection .

  • Counterstain nuclei with DAPI for localization context .

• Expected localization pattern:

  • TRAM typically shows cytoplasmic localization across different cell types .

  • Use appropriate positive controls (e.g., Raji, C2C12, NRK cells) to confirm staining patterns .

What controls should be implemented to validate TRAM antibody specificity?

Rigorous validation of TRAM antibody specificity requires multiple controls:

• Positive controls:

  • Cell lines with confirmed TRAM expression: Raji, C2C12, NRK, HeLa, Jurkat, and 293T cells .

  • Tissue samples: Rat brain, kidney, and mouse placenta .

• Negative controls:

  • Isotype control antibodies (e.g., AB-108-C has been used as control for TRAM antibodies) .

  • Primary antibody omission controls to assess secondary antibody specificity.

  • TRAM-knockdown samples if available.

• Cross-validation approaches:

  • Compare results across antibodies targeting different TRAM epitopes.

  • Correlate protein detection with transcript expression data.

  • For flow cytometry, compare filled histograms (TRAM staining) with open histograms (isotype controls) to distinguish specific from non-specific signals .

How can TRAM antibodies be optimized for flow cytometry analysis?

For flow cytometric detection of TRAM, implement these specialized protocols:

• Cell preparation:

  • Since TRAM is primarily intracellular, fixation with paraformaldehyde and permeabilization with saponin is essential .

  • Optimize fixation time to maintain cellular integrity while enabling antibody access.

• Antibody staining parameters:

  • Use validated TRAM antibodies with appropriate fluorophore-conjugated secondary antibodies.

  • For AF4348, detection has been validated using Phycoerythrin-conjugated Anti-Goat IgG Secondary Antibody (F0107) .

  • For staining C2C12 and NRK cells, Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody (F0108) has been effective .

• Controls and analysis:

  • Include isotype control antibodies (e.g., AB-108-C) to establish gating thresholds .

  • Analyze both percentage of positive cells and mean fluorescence intensity.

  • Consider multiparameter analysis to correlate TRAM expression with activation markers or cell-type-specific markers.

• Data interpretation:

  • Expect varying expression levels across different cell types.

  • Consider potential differences in accessibility of the TRAM epitope depending on activation state.

What are effective strategies for troubleshooting weak or non-specific TRAM detection?

When encountering challenges with TRAM antibody applications, consider these methodological solutions:

• For weak signal in Western blot:

  • Increase protein loading (30-50 μg total protein).

  • Extend primary antibody incubation time (overnight at 4°C).

  • Implement signal enhancement methods (enhanced chemiluminescence reagents).

  • Optimize transfer conditions for proteins in TRAM's molecular weight range.

• For high background in immunofluorescence:

  • Increase blocking stringency (5% BSA or 5-10% normal serum from secondary antibody host species).

  • Extend washing steps (4-5 washes of 5-10 minutes each).

  • Titrate primary and secondary antibodies to identify optimal concentrations.

  • Consider autofluorescence quenching methods if using tissues.

• For multiple bands in Western blot:

  • Verify sample integrity with fresh protease inhibitors.

  • Consider native TRAM isoforms or post-translational modifications.

  • Test alternative antibodies targeting different epitopes.

  • Include positive control lysates with confirmed TRAM expression pattern .

How can TRAM antibodies be used to investigate TLR4 signaling pathway dynamics?

TRAM antibodies enable sophisticated analyses of TLR4 signaling mechanisms:

• Co-immunoprecipitation studies:

  • Use TRAM antibodies to precipitate protein complexes and identify interaction partners.

  • Investigate stimulus-dependent changes in TRAM-associated proteins following TLR4 activation.

  • Compare MyD88-dependent versus independent signaling complex formation.

• Pathway activation kinetics:

  • Combine with phospho-specific antibodies to monitor downstream signaling events.

  • Perform time-course experiments following LPS stimulation to track TRAM recruitment.

  • Compare TRAM localization and activation in different cell types with varying TLR4 responses.

• Subcellular fractionation analysis:

  • Use Western blotting with TRAM antibodies to track protein translocation between cellular compartments.

  • Investigate the kinetics of TRAM trafficking following pathway activation.

  • Compare membrane association versus cytoplasmic localization under different conditions.

How can TRAM antibodies contribute to antibody design and optimization research?

TRAM antibodies can be valuable tools in antibody engineering research:

• Structural validation:

  • Use established TRAM antibodies as benchmarks when developing new antibody design methodologies .

  • Apply deep learning models like those used for antibody Fv structure prediction to understand epitope recognition .

• Affinity assessment:

  • Implement log-likelihood scoring methods to rank potential antibody designs, as demonstrated in recent antibody optimization research .

  • Compare binding characteristics across different antibody formats targeting the same TRAM epitope.

• Thermostability evaluation:

  • Assess thermal and colloidal stability parameters (Tonset, Tm, Tagg) of TRAM antibodies as part of broader antibody optimization strategies .

  • Use high-throughput methods to test multiple TRAM antibody variants for stability and specificity.

What considerations are important when using TRAM antibodies in multiplex imaging applications?

For successful multiplex imaging with TRAM antibodies:

• Antibody compatibility planning:

  • Select primary antibodies from different host species to prevent cross-reactivity.

  • If using AF4348 (goat host), pair with rabbit, mouse, or rat-derived antibodies against other targets .

• Fluorophore selection strategy:

  • Choose spectrally distinct fluorophores that minimize bleed-through.

  • NorthernLights™ 557-conjugated secondary antibodies have been validated for TRAM detection and can be paired with other fluorophores in different channels .

• Sequential staining considerations:

  • If using multiple primary antibodies from the same species, implement sequential staining protocols with appropriate blocking steps.

  • Validate each antibody individually before combining in multiplex protocols.

• Analysis approaches:

  • Use appropriate image analysis tools to quantify co-localization between TRAM and other proteins of interest.

  • Implement spectral unmixing for closely overlapping fluorophores.

How can researchers integrate TRAM antibodies into experimental systems studying the interplay between innate and adaptive immunity?

TRAM antibodies enable mechanistic studies of immune pathway cross-regulation:

• Dendritic cell activation studies:

  • Use TRAM antibodies to track adaptor recruitment during dendritic cell maturation.

  • Correlate TRAM-dependent signaling with antigen presentation capacity.

  • Investigate how TRAM-mediated pathways influence T cell priming outcomes.

• Macrophage polarization analysis:

  • Compare TRAM expression and localization between M1 and M2 macrophage phenotypes.

  • Investigate how TRAM-dependent signaling influences macrophage functional responses.

  • Correlate with downstream cytokine production profiles.

• Cross-talk with adaptive immune signaling:

  • Use co-immunoprecipitation with TRAM antibodies to identify novel interaction partners linking innate and adaptive pathways.

  • Investigate how T cell-derived signals modulate TRAM-dependent responses in innate immune cells.

  • Implement temporal analysis to understand sequential activation of interconnected pathways.

What are the latest methodological advances for high-sensitivity detection of TRAM in challenging samples?

Recent innovations have enhanced TRAM detection capabilities:

• Signal amplification technologies:

  • Tyramide signal amplification can substantially increase sensitivity for samples with low TRAM expression.

  • Proximity ligation assay (PLA) methods can detect TRAM interactions with increased sensitivity and spatial resolution.

  • Implementation of photoswitchable fluorophores for super-resolution microscopy of TRAM localization.

• Enhanced antigen retrieval approaches:

  • For TRAM1 antibody applications in tissues, TE buffer pH 9.0 is recommended, though citrate buffer pH 6.0 may serve as an alternative .

  • Optimization of retrieval time and temperature can significantly improve detection in fixed tissues.

• Advanced detection instrumentation:

  • High-sensitivity imaging systems with improved signal-to-noise capabilities.

  • Automated image acquisition and analysis platforms for standardized quantification.

  • Integration with artificial intelligence-based image analysis for complex pattern recognition.

How can researchers effectively validate novel TRAM antibodies as part of antibody development programs?

Comprehensive validation of new TRAM antibodies requires systematic approaches:

• Epitope mapping and characterization:

  • Identify the specific TRAM regions recognized by the antibody.

  • Assess conservation of these epitopes across species to predict cross-reactivity.

  • Determine whether the epitope is accessible in the native protein conformation.

• Comprehensive application testing:

  • Systematically evaluate performance across all potential applications (WB, IHC, IF, Flow Cytometry).

  • Test in multiple cell types and tissues with varying TRAM expression levels.

  • Compare performance against established TRAM antibodies.

• Specificity confirmation:

  • Use TRAM knockout/knockdown systems for definitive specificity validation.

  • Perform peptide competition assays to confirm epitope-specific binding.

  • Evaluate potential cross-reactivity with other TIR domain-containing proteins.

• Reproducibility assessment:

  • Test multiple antibody lots to ensure consistent performance.

  • Validate across different laboratories and experimental conditions.

  • Document optimal protocols for each application to ensure reproducibility.